Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

We expect Sanofi to remain on solid financial footing. It closed 2024 with a debt/EBITDA ratio of 1.7 times. The company generates stable cash flows from a diverse product portfolio, which should ...

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD Drug is cleared for 300,000 U.S. patients with a form of the lung disease driven by eosinophils Wikimedia Commons By Jonathan Wosen ...